Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
Aladag
Murat
M
Camci
Cemal
C
Huang
Ye
Y
Wright
Harlan
H
Rizvi
Sayed
S
Gurakar
Ahmet
A
Stokes
Kenneth
K
Sebastian
Anthony
A
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood / Q000209:etiology; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D000509:alpha-Fetoproteins / Q000187:drug effects / Q000378:metabolism*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a